Alzheimer’s disease |
171 |
71 |
104 |
104 |
2.10E-07 |
5.03E-05 |
Oxidative phosphorylation |
133 |
55.2 |
84 |
84 |
3.16E-07 |
5.03E-05 |
Parkinson’s disease |
142 |
58.9 |
88 |
88 |
5.66E-07 |
6.00E-05 |
Chemokine signaling pathway |
190 |
78.9 |
105 |
105 |
7.50E-05 |
0.00596 |
Malaria |
49 |
20.3 |
33 |
33 |
0.000221 |
0.0141 |
Dopaminergic synapse |
131 |
54.4 |
74 |
74 |
0.000346 |
0.0173 |
Phagosome |
152 |
63.1 |
84 |
84 |
0.000381 |
0.0173 |
Spliceosome |
134 |
55.6 |
75 |
75 |
0.000463 |
0.0184 |
Non-alcoholic fatty liver disease (NAFLD) |
149 |
61.8 |
82 |
82 |
0.00053 |
0.0187 |
Chagas disease (American trypanosomiasis) |
103 |
42.7 |
59 |
59 |
0.000832 |
0.0265 |
Notch signaling pathway |
48 |
19.9 |
31 |
31 |
0.00102 |
0.0295 |
Protein processing in endoplasmic reticulum |
165 |
68.5 |
88 |
88 |
0.00129 |
0.0316 |
Salmonella infection |
86 |
35.7 |
50 |
50 |
0.00129 |
0.0316 |
Platelet activation |
124 |
51.5 |
68 |
68 |
0.00173 |
0.0387 |
Pathogenic Escherichia coli infection |
55 |
22.8 |
34 |
34 |
0.00182 |
0.0387 |
Huntington’s disease |
193 |
80.1 |
100 |
100 |
0.00218 |
0.0434 |
Pathways in cancer |
530 |
220 |
251 |
251 |
0.00274 |
0.051 |
Osteoclast differentiation |
128 |
53.1 |
69 |
69 |
0.00289 |
0.051 |
Fc gamma R-mediated phagocytosis |
91 |
37.8 |
51 |
51 |
0.00343 |
0.0575 |
Complement and coagulation cascades |
79 |
32.8 |
45 |
45 |
0.00383 |
0.0609 |
Oxytocin signaling pathway |
153 |
63.5 |
80 |
80 |
0.00423 |
0.064 |
Th1 and Th2 cell differentiation |
92 |
38.2 |
51 |
51 |
0.00464 |
0.0671 |
Epithelial cell signaling in Helicobacter pylori infection |
68 |
28.2 |
39 |
39 |
0.00586 |
0.0773 |
Hematopoietic cell lineage |
97 |
40.3 |
53 |
53 |
0.00587 |
0.0773 |
Leukocyte transendothelial migration |
112 |
46.5 |
60 |
60 |
0.00627 |
0.0773 |
Tight junction |
170 |
70.6 |
87 |
87 |
0.00632 |
0.0773 |
Apoptosis |
136 |
56.4 |
71 |
71 |
0.00711 |
0.0838 |
FoxOsignaling pathway |
132 |
54.8 |
69 |
69 |
0.0076 |
0.0863 |
Mitophagy - animal |
65 |
27 |
37 |
37 |
0.00845 |
0.0882 |
Shigellosis |
65 |
27 |
37 |
37 |
0.00845 |
0.0882 |
Prion diseases |
35 |
14.5 |
22 |
22 |
0.00867 |
0.0882 |
Primary immunodeficiency |
37 |
15.4 |
23 |
23 |
0.00888 |
0.0882 |
Epstein-Barr virus infection |
201 |
83.4 |
100 |
100 |
0.0102 |
0.0932 |
Pertussis |
76 |
31.5 |
42 |
42 |
0.0104 |
0.0932 |
Focal adhesion |
199 |
82.6 |
99 |
99 |
0.0105 |
0.0932 |
Calcium signaling pathway |
188 |
78 |
94 |
94 |
0.0106 |
0.0932 |
Amphetamine addiction |
68 |
28.2 |
38 |
38 |
0.0114 |
0.098 |
Vibrio cholerae infection |
50 |
20.8 |
29 |
29 |
0.0134 |
0.112 |
Regulation of actin cytoskeleton |
214 |
88.8 |
105 |
105 |
0.0141 |
0.113 |
Retrograde endocannabinoid signaling |
148 |
61.4 |
75 |
75 |
0.0143 |
0.113 |
HTLV-I infection |
219 |
90.9 |
107 |
107 |
0.0153 |
0.119 |
Kaposi’s sarcoma-associated herpesvirus infection |
186 |
77.2 |
92 |
92 |
0.016 |
0.119 |
Carbon metabolism |
116 |
48.1 |
60 |
60 |
0.016 |
0.119 |
Endocytosis |
244 |
101 |
118 |
118 |
0.0164 |
0.119 |
Phosphatidylinositol signaling system |
99 |
41.1 |
52 |
52 |
0.0168 |
0.119 |
Legionellosis |
55 |
22.8 |
31 |
31 |
0.0182 |
0.126 |
Chronic myeloid leukemia |
76 |
31.5 |
41 |
41 |
0.0187 |
0.126 |
Proteasome |
45 |
18.7 |
26 |
26 |
0.0199 |
0.132 |
Hippo signaling pathway -multiple species |
29 |
12 |
18 |
18 |
0.0203 |
0.132 |
Proteoglycans in cancer |
201 |
83.4 |
98 |
98 |
0.021 |
0.134 |
Ribosome |
153 |
63.5 |
76 |
76 |
0.0239 |
0.149 |
Cellular senescence |
160 |
66.4 |
79 |
79 |
0.0255 |
0.156 |
B cell receptor signaling pathway |
71 |
29.5 |
38 |
38 |
0.0267 |
0.16 |
2-Oxocarboxylic acid metabolism |
18 |
7.47 |
12 |
12 |
0.0276 |
0.161 |
Circadian entrainment |
97 |
40.3 |
50 |
50 |
0.0283 |
0.161 |
Long-term potentiation |
67 |
27.8 |
36 |
36 |
0.0285 |
0.161 |
ECM-receptor interaction |
82 |
34 |
43 |
43 |
0.0289 |
0.161 |
Basal cell carcinoma |
63 |
26.1 |
34 |
34 |
0.0303 |
0.166 |
Autophagy - animal |
128 |
53.1 |
64 |
64 |
0.0309 |
0.166 |
Apelinsignaling pathway |
137 |
56.9 |
68 |
68 |
0.0319 |
0.169 |
Cell adhesion molecules (CAMs) |
146 |
60.6 |
72 |
72 |
0.0328 |
0.171 |
Adherens junction |
72 |
29.9 |
38 |
38 |
0.0344 |
0.173 |
Arrhythmogenic right ventricular cardiomyopathy (ARVC) |
72 |
29.9 |
38 |
38 |
0.0344 |
0.173 |
Natural killer cell mediated cytotoxicity |
131 |
54.4 |
65 |
65 |
0.0356 |
0.177 |
Non-small cell lung cancer |
66 |
27.4 |
35 |
35 |
0.0381 |
0.186 |
Glucagon signaling pathway |
103 |
42.7 |
52 |
52 |
0.0398 |
0.188 |
Oocyte meiosis |
125 |
51.9 |
62 |
62 |
0.0398 |
0.188 |
Cytokine-cytokine receptor interaction |
294 |
122 |
137 |
137 |
0.0407 |
0.188 |
Hippo signaling pathway |
154 |
63.9 |
75 |
75 |
0.0408 |
0.188 |
Endometrial cancer |
58 |
24.1 |
31 |
31 |
0.0436 |
0.198 |
Fructose and mannose metabolism |
33 |
13.7 |
19 |
19 |
0.0455 |
0.204 |
cGMP-PKG signaling pathway |
166 |
68.9 |
80 |
80 |
0.0462 |
0.204 |
IL-17 signaling pathway |
93 |
38.6 |
47 |
47 |
0.0479 |
0.209 |
Rheumatoid arthritis |
91 |
37.8 |
46 |
46 |
0.0497 |
0.214 |